USA flag logo/image

An Official Website of the United States Government

Development of rapid detection tests for Brucella species

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
79732
Program Year/Program:
2006 / SBIR
Agency Tracking Number:
AI068166
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2006
Title: Development of rapid detection tests for Brucella species
Agency: HHS
Contract: 1R43AI068166-01A1
Award Amount: $607,822.00
 

Abstract:

DESCRIPTION (provided by applicant): Brucellosis is a re-emerging zoonotic disease that affects humans and a variety of farm animals. As well as a threat to public health it has considerable economic importance. The etiologic agent responsible for human infection, Brucella melitensis, is classified by both NIAID and CDC as a Category B biothreat pathogen. Antibiotics are only partially effective at controlling the disease and there is no vaccine approved for use in humans. Thus prompt and accurate diagnosis is the key to containing infection. Currently the most common diagnostic tests for Brucella are based on indirect serology which are lacking in specificity and sensitivity as well as speed of execution. Thus there is a pressing need to develop improved diagnostics, especially technologies that may be used at field level. This investigation proposes to address this issue and develop a superior and robust technique for diagnosing Brucella infection with highly specific, non- cross reactive antibody reactions. We will achieve this goal by screening the Brucella genome using novel proteomic chip technology to identify unique antigens that will yield highly specific and accurate diagnoses. This work will be undertaken in Phase 1 of the application. In Phase 2, when antigens have been selected, we anticipate that we will proceed to develop ELISA and immunoblot assays. In parallel both ELISA and lateral flow "dipstick" tests for Brucella antigen will be constructed. We envisage that the antigen assays will have particular utility in detecting Brucella disseminated in the context of the bioterrorism event. The diagnostic tools developed within this application will be rigorously evaluated for sensitivity and specificity using large and diverse panels of human and animal Brucella-positive sera available through our collaborators. The project proposes to develop a highly sensitive and robust diagnostic test for brucellosis, also known as "undulant fever", an infectious disease that causes serious illness in farm animals and humans. The current techniques for diagnosing infection are somewhat unreliable and based on outmoded methods. This investigation will use state- of-the-art technology to identify new structures or antigens on Brucella bacteria that may be used to develop a test with superior diagnostic performance.

Principal Investigator:

William J. Morrow
2063445821
wjwmorrow@inbios.com

Business Contact:


2063445821
Small Business Information at Submission:

INBIOS INTERNATIONAL, INC.
562 1ST AVE. SOUTH, SUITE 600 SEATTLE, WA 98104

EIN/Tax ID: 911791824
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No